An antigen produced by splicing of noncontiguous peptides in the reverse order. - Wikidata - wikimedia - TriplyDB

An antigen produced by splicing of noncontiguous peptides in the reverse order.

An antigen produced by splicing of noncontiguous peptides in the reverse order.

http://www.wikidata.org/entity/Q34564542

about

Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets Database of T cell-defined human tumor antigens: the 2013 update Investigation of Serine-Proteinase-Catalyzed Peptide Splicing in Analogues of Sunflower Trypsin Inhibitor 1 (SFTI-1)Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications.Graft-versus-host disease: a surge of developments C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.The 20S proteasome splicing activity discovered by SpliceMet.Pathways of antigen processing.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.An antigenic peptide produced by reverse splicing and double asparagine deamidation Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors Driving forces of proteasome-catalyzed peptide splicing in yeast and humans.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules New lane in the information highway: alternative reading frame peptides elicit T cells with potent antiretrovirus activity.Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.Identification of T-cell epitopes for cancer immunotherapy.Diversity of proteasomal missions: fine tuning of the immune response.Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.Towards a liquid self: how time, geography, and life experiences reshape the biological identity.Adoptive T-cell therapy for B-cell malignancies.Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.The role of the proteasome in the generation of MHC class I ligands and immune responses.A peptide's perspective on antigen presentation to the immune system.

P2860

Q24652244-727FECA3-B63D-40C4-8CEC-42DAB7632799 Q26750999-F59D6185-665E-4C31-BAF7-45979C950382 Q27022422-20A1D214-7BC8-4118-B21A-7D7972D3AFBA Q27701655-1EB42BE3-2A41-44F4-9FC8-1628704BACA6 Q30665275-03EEDCE6-3485-4CC6-8A86-56CB22B14F13 Q33267303-023DBD56-B2C9-435A-959D-89B0D1B4DBB8 Q33290423-14DBB53A-E4E9-476C-8EF4-070B99071600 Q33359498-712EBB9B-611D-49FB-982B-54EF77073013 Q33627497-EF99D89D-320A-4AAC-92F8-4FC95D29CD9A Q33631854-9047F6F9-EA9A-4A27-91F9-A7DB826A3307 Q33648677-0730E824-57F1-41C3-B5F3-3BDD5912A793 Q33709766-0F552EC0-1D8B-4E2A-961F-AB7C6350E8B5 Q33723635-310767F6-2645-486E-AF88-43E9082911F9 Q33931811-1AB1542D-F215-494F-9725-3D7A5D15F29B Q33952256-388E997E-274E-4E31-9692-2912B6E7A8C3 Q34163218-80073CC3-6D9E-4337-BA85-14A86C06C31E Q34192290-0BC90BBB-2836-48B8-9142-CF451E6FD3AF Q34314427-53E9D9C4-33E6-4BEE-B043-E1BCE840BB5A Q34347732-E7947BC3-3C3F-4F0D-8243-6110333F01E7 Q35042764-39F16128-E726-48C5-B2D1-421E8DD14765 Q35446852-96751B3F-1BAF-4A6B-ACE9-52450D5B834A Q35786206-89DD5E9A-A4B4-492C-B43D-1EF7433D257F Q36229113-E9A4BD0A-61EE-4801-9D2E-4AD051C6F59D Q36556944-DDA0825D-32ED-4836-AB87-021D2FE415D7 Q36662079-B7F1420D-CD29-4835-A16E-5D0E322E3C79 Q36769053-11DF5C13-5156-4EAD-824A-36B1FA3CAF63 Q36827004-865F6791-CE44-42F5-BE62-F69ADA5CE6DA Q36830199-5BF2C778-F83D-40FE-A834-42E43B273DEF Q36870592-25F8346F-EAC9-4181-B591-7EEE8341522F Q36909248-10BDB011-9AF4-4382-B781-FED959105345 Q36945852-465DE35B-9159-4298-83A6-1E5B0F2EE53B Q36979992-060E01AF-6052-4E8D-A786-35709B8D20B0 Q36994811-8019F110-C108-4CCC-B2FF-3EAF680B7F5B Q37341897-D83749CD-5156-4AD5-9DE7-876FF293CA0E Q37705431-D89DBAAB-D927-4BB0-B83B-C80E10D8D83B Q37810116-031139F5-1740-49C0-892E-5E4D4CEA47F8 Q37851048-D79DE359-394C-4622-8CAA-2A96A0CB6BF0 Q37851050-52914FCD-4A9A-48A2-8F77-E8E1729C6753 Q37851052-7A2563B5-8A8A-4ECB-9420-4F6DB9C173A8 Q38162671-03964577-B294-491A-8555-285C217C9D86

P2860

An antigen produced by splicing of noncontiguous peptides in the reverse order.

http://www.wikidata.org/entity/Q34564542

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@ast

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@en

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@nl

type

label

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@ast

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@en

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@nl

prefLabel

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@ast

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@en

An antigen produced by splicing of noncontiguous peptides in the reverse order.

@nl

P1433

Q34564542-BBF74D89-86B6-4EEB-8DFF-633599100E89

P1476

Q34564542-383E5838-9582-4205-844F-DBD3467E16FD

P2093

Q34564542-20D5AD0E-9B61-4CC0-9202-14A2CBD511CF

Q34564542-31DBF040-4CD8-40D9-8C3A-0A933A05211A

Q34564542-336ACAD4-2C3E-4035-8F34-15923B8BB00A

Q34564542-4B2EAB0C-FB50-432D-8EAE-D8A67EE34090

Q34564542-6BADAAF2-8A5E-4103-99E9-37247A222253

Q34564542-6FAB8E6E-0C12-4D8E-AA33-580FDC40D6BE

Q34564542-A619E58A-665A-4621-97C7-53EF7194AB09

Q34564542-C04BDBAD-559B-4703-B237-FC6DEF450D9B

Q34564542-CEC96CE9-32AF-4116-B1E3-D695F1EF7A04

Q34564542-EEE89C0E-92C0-4778-95CD-6EC224E610DA

P2860

Q34564542-3CCBB581-DE26-4737-8596-30F471DA5647

Q34564542-40549749-8AC0-4F57-8A34-C53CFB2A0493

Q34564542-4119788F-D9B2-43D4-B4E3-1FA2A0221036

Q34564542-4371A4E8-9D54-4C52-B74E-F59D788E6C94

Q34564542-64F1DA64-239D-479B-A768-6E9D85DDFE31

Q34564542-6FC34253-9A1B-4AD6-8C1A-8A67B4AAAA6A

Q34564542-B32E9EFC-D634-479A-97EA-36C431BCD3E2

Q34564542-CFB963CC-4DF4-4567-8C3F-CEFD82951712

Q34564542-D910C8E0-C2C4-49E8-A750-0E03C7BB48D1

Q34564542-E4DB3284-DA76-4422-8DDE-F0A36FD10D64

P304

Q34564542-00233C88-180F-4E37-9B3B-1C7F7E12385E

P31

Q34564542-7E924968-2475-4297-8928-22B4AFBADA7D

P356

Q34564542-820FB086-E1EC-4F98-BDBC-F4B679C56A83

P407

Q34564542-E18B37A7-E14F-488B-A5E2-D2ACAD108734

P433

Q34564542-C26DDD71-23D7-4491-9390-879B9A87ADD4

P478

Q34564542-A45C0432-3832-40EC-9FE1-CF2EEDE6B697

P50

Q34564542-33B277AC-6582-486A-BCAE-3ED3EFCF112D

P577

Q34564542-9D703200-B27D-46AB-A688-4DC5B460B312

P698

Q34564542-10B25BD3-6906-4237-BBF5-B63B0421C8AF

P356

SCIENCE.1130660

P1433

P1476

An antigen produced by splicing of noncontiguous peptides in the reverse order

@en

P2093

Alexandre Dalet

http://www.w3.org/2001/XMLSchema#string

Benoît J Van den Eynde

http://www.w3.org/2001/XMLSchema#string

Jeffrey K Mito

http://www.w3.org/2001/XMLSchema#string

Marc A Gavin

http://www.w3.org/2001/XMLSchema#string

Nathalie J Vigneron

http://www.w3.org/2001/XMLSchema#string

Pierre G Coulie

http://www.w3.org/2001/XMLSchema#string

Scott S Tykodi

http://www.w3.org/2001/XMLSchema#string

Stanley R Riddell

http://www.w3.org/2001/XMLSchema#string

Suzanne M Xuereb

http://www.w3.org/2001/XMLSchema#string

Vincent Stroobant

http://www.w3.org/2001/XMLSchema#string

P2860

Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator

Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone.

Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-dependent processing.

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

Degradation of cell proteins and the generation of MHC class I-presented peptides.

An antigenic peptide produced by peptide splicing in the proteasome.

Molecules and mechanisms of the graft-versus-leukaemia effect.

CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells

Making sense of mass destruction: quantitating MHC class I antigen presentation.

Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides.

P304

1444-1447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1130660

http://www.w3.org/2001/XMLSchema#string

P407

P433

5792

http://www.w3.org/2001/XMLSchema#string

P478

313

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16960008

http://www.w3.org/2001/XMLSchema#string